Table 4_Exploring the celecoxib–cervical cancer relationship using in vitro, network pharm

A 31.7 KB Excel file contains results from a study investigating the anticancer role of celecoxib. The dataset likely includes statistical outputs from Mendelian randomization analyses, in vitro assay results, and network pharmacology findings. The data was authored by Tongfei Wang and last updated in May 2026.

Use Cases

• Validate causal relationships between drug targets and cancer risk based on Mendelian randomization results.
• Analyze the effect of NEU1 inhibition on cervical cancer based on the reported odds ratio.
• Investigate immune cell mediation pathways, specifically CD25 on CD45RA+ CD4+ non-regulatory T cells.
• Correlate in vitro assay results (proliferation, migration, invasion) with genetic inference findings.

Strengths

• Dataset integrates three distinct methodological approaches: in vitro assays, network pharmacology, and Mendelian randomization.
• Mendelian randomization analysis provides a specific odds ratio (OR = 0.736) and confidence interval for NEU1 inhibition effect.
• The study quantifies mediation effects, reporting CD25 on specific T cells mediated 28.458% of the total effect.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small (31.7 KB), indicating limited scope and likely summary-level results rather than raw experimental data.

Provenance

Source

figshare

Collection Method

Results from integrated laboratory experiments, computational network analysis, and genetic causal inference.

Freshness

Last updated 2026-05-19 05:41:47; freshness should be verified.